Efgartigimod alfa for immunoglobulin g4-related disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 17 Jun 2025: Trial registered, NCT07025330
  2. 12 Nov 2025: Trial started, NCT07025330

The trials

NCT07025330: A Study of Efgartigimod in Patients With IgG4-Related Disease

State
Under way
Phase
Phase 2
People
5 planned
Started
12 Nov 2025
Primary completion
1 Mar 2028
Arms
efgartigimod
Results
None posted
  1. 17 Jun 2025: Trial registered
  2. 12 Nov 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Also known as Efgartigimod, Efgartigimod IV.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.